

The CXCL12gamma chemokine displays unprecedented structural and functional properties that make it a paradigm of chemoattractant proteins.

Patricia Rueda, Karl Balabanian, Bernard Lagane, Isabelle Staropoli, Ken Chow, Angélique Levoye, Cédric Laguri, Rabia Sadir, Thierry Delaunay, Elena Izquierdo, et al.

► **To cite this version:**

Patricia Rueda, Karl Balabanian, Bernard Lagane, Isabelle Staropoli, Ken Chow, et al.. The CXCL12gamma chemokine displays unprecedented structural and functional properties that make it a paradigm of chemoattractant proteins.. PLoS ONE, Public Library of Science, 2008, 3 (7), pp.e2543. 10.1371/journal.pone.0002543 . pasteur-00315593

HAL Id: pasteur-00315593

<https://hal-pasteur.archives-ouvertes.fr/pasteur-00315593>

Submitted on 2 Oct 2008

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

The CXCL12 γ Chemokine Displays Unprecedented Structural and Functional Properties that Make It a Paradigm of Chemoattractant Proteins

Patricia Rueda^{1,2,3}, Karl Balabanian^{2,3*}, Bernard Lagane^{2,3}, Isabelle Staropoli^{2,3}, Ken Chow^{2,3}, Angélique Levoye^{2,3}, Cedric Laguri⁴, Rabia Sadir⁴, Thierry Delaunay⁵, Elena Izquierdo⁶, Jose Luis Pablos⁶, Elena Lendinez¹, Antonio Caruz¹, Diego Franco¹, Françoise Baleux⁷, Hugues Lortat-Jacob⁴, Fernando Arenzana-Seisdedos^{2,3*}

1 Departamento de Biología Experimental, Universidad de Jaén, Jaén, Spain, **2** Viral Pathogenesis laboratory, Institut Pasteur, Paris, France, **3** INSERM U819, Paris, France, **4** Institute for Structural Biology, Gagophile laboratory UMR 5075 CNRS-CEA-UJF, Grenoble, France, **5** INRA, Villenave d'Ornon, France, **6** Servicio de Reumatología y Unidad de Investigación, Hospital 12 de Octubre, Madrid, Spain, **7** Unité de Chimie Organique, Institut Pasteur, Paris, France

Abstract

The CXCL12 γ chemokine arises by alternative splicing from *Cxcl12*, an essential gene during development. This protein binds CXCR4 and displays an exceptional degree of conservation (99%) in mammals. CXCL12 γ is formed by a protein core shared by all CXCL12 isoforms, extended by a highly cationic carboxy-terminal (C-ter) domain that encompasses four overlapped BBXB heparan sulfate (HS)-binding motifs. We hypothesize that this unusual domain could critically determine the biological properties of CXCL12 γ through its interaction to, and regulation by extracellular glycosaminoglycans (GAG) and HS in particular. By both RT-PCR and immunohistochemistry, we mapped the localization of CXCL12 γ both in mouse and human tissues, where it showed discrete differential expression. As an unprecedented feature among chemokines, the secreted CXCL12 γ strongly interacted with cell membrane GAG, thus remaining mostly adsorbed on the plasmatic membrane upon secretion. Affinity chromatography and surface plasmon resonance allowed us to determine for CXCL12 γ one of the higher affinity for HS ($K_d = 0.9$ nM) ever reported for a protein. This property relies in the presence of four canonical HS-binding sites located at the C-ter domain but requires the collaboration of a HS-binding site located in the core of the protein. Interestingly, and despite reduced agonist potency on CXCR4, the sustained binding of CXCL12 γ to HS enabled it to promote *in vivo* intraperitoneal leukocyte accumulation and angiogenesis in matrigel plugs with much higher efficiency than CXCL12 α . In good agreement, mutant CXCL12 γ chemokines selectively devoid of HS-binding capacity failed to promote *in vivo* significant cell recruitment. We conclude that CXCL12 γ features unique structural and functional properties among chemokines which rely on the presence of a distinctive C-ter domain. The unsurpassed capacity to bind to HS on the extracellular matrix would make CXCL12 γ the paradigm of haptotactic proteins, which regulate essential homeostatic functions by promoting directional migration and selective tissue homing of cells.

Citation: Rueda P, Balabanian K, Lagane B, Staropoli I, Chow K, et al. (2008) The CXCL12 γ Chemokine Displays Unprecedented Structural and Functional Properties that Make It a Paradigm of Chemoattractant Proteins. PLoS ONE 3(7): e2543. doi:10.1371/journal.pone.0002543

Editor: Jeffrey A. Gold, Oregon Health & Science University, United States of America

Received: April 11, 2008; **Accepted:** May 15, 2008; **Published:** July 2, 2008

Copyright: © 2008 Rueda et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work is supported by grants from the French Agence National pour la Recherche (ANR), the Agence National pour la Recherche sur le SIDA (ANRS) Institut National de la Santé et la Recherche Médicale (INSERM), Institut Pasteur and Fondo de Investigaciones Sanitarias (Spain, FIS 05/060). PR is a fellowship recipient from the FPD program sponsored by the Andalucía autonomous government (Spain). KC and AL are supported by Croucher Foundation (Hong Kong) and ANR-Maladies Rares, respectively. CL is supported by an ANR postdoctoral grant.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: farenzan@pasteur.fr

‡ Current address: INSERM U764, Université Paris-Sud 11, Faculté de Médecine Paris Sud, Institut Fédératif de Recherche 13, Clamart, France

Introduction

The CXC chemokine, stromal cell-derived factor 1/CXCL12 [1] is a constitutive and broadly expressed chemokine that exerts its functions through the G-protein coupled receptor (GPCR) CXCR4 [2]. Recently, a novel receptor for CXCL12, RDC-1/CXCR7, has been identified [3–5]. Mouse and human CXCL12 α , the major CXCL12 isoform, differ by a single, homologous substitution (Val18 to Ile18) [1,6] and each protein owns the capacity to bind and activate the orthologue CXCR4

receptor. The exceptional conservation of both CXCR4 and CXCL12 structure and function in mammals announces the essential roles played by this singular couple. CXCL12 is unique among the family of chemokines as it plays non-redundant roles during embryo life in the development of both cardiovascular [7] and central nervous system [8,9], hematopoiesis [10] and colonization of the gonads by primordial germ cells [11]. In the post-natal life, CXCL12 is involved in trans-endothelial migration of leukocytes [12–15] and regulates critically both the homing and egress of CD34+CXCR4+progenitor cells from the bone marrow,

and their migration into peripheral tissues [16]. CXCL12 also plays a prominent role in physiopathological processes such as inflammation [17], angiogenesis and wound healing [18,19]. Moreover, CXCL12 is a critical factor for growth, survival and metastatic dissemination of a number of tumors [20].

The engagement of CXCR4 by CXCL12 triggers the activation of heterotrimeric G $\alpha\beta\gamma$ -proteins, which ultimately promote the directional migration of cells towards a concentration gradient of ligand that defines the haptotactic function of chemokines. *In vivo*, chemokines are believed to form gradient concentrations by binding to glycosaminoglycans (GAG), the glycanic moieties of proteoglycans, and in particular to heparan sulfate (HS). Electrostatic contacts between the negatively charged HS and basic residues exposed at the surface of chemokines, along with structural features of the oligosaccharide, determine both the affinity and the specificity of the molecular interactions that are supposed to modulate the *in vivo* biological activity of chemokines complexed to proteoglycans [21–24].

The study of the well characterized CXCL12 α isoform provided most of the knowledge of CXCL12 biological properties including interaction with GAG, which is essentially accounted for by a canonical BBXB (B for basic amino-acids, X any other amino-acid) HS-binding motif, located in the first β -strand of the protein [25]. In contrast, the novel CXCL12 γ isoform remains largely unexplored regarding protein expression and biological function. CXCL12 γ is formed by a core domain encompassing the 68 amino-acids of the major CXCL12 α isoform shared with all CXCL12 proteins, which is extended by a carboxy-terminal (C-ter) domain. This region, highly-enriched in basic amino-acids, encodes four overlapped HS-binding motifs and shows identical sequence in human, rat and mouse species [6,26,27]. This positively charged domain enables CXCL12 γ with an amazing capacity to interact with GAG [28]. We speculated that this property might be determinant in defining the *in vivo* capacity of this peculiar chemokine to promote both migration and homing of cells in tissues. In this work we characterized CXCL12 γ tissue expression and the capacity of this isoform to interact with CXCR4 and promote cell migration *in vitro*. Moreover, we investigated the interaction of CXCL12 γ with GAG both *in vitro* and on intact cells. Finally, we assessed the functionality of this novel isoform *in vivo*. Our findings indicate that CXCL12 γ displays a sustained binding on GAG and exhibits a prolonged chemokine activity *in vivo* that makes it a paradigm among haptotactic proteins. The intactness of the BBXB sites in the distinctive CXCL12 γ C-ter domain critically determine the biological activity of the chemokine.

Results

Tissue distribution of Cxcl12 γ products

The *Cxcl12 γ* isoform cDNA was obtained from BALB/c mouse brain mRNA. The isolated cDNA nucleotide sequence was identical to the previously reported murine *Cxcl12 γ* isoform (GenBank NCBI accession number NM_001012477) that encodes the CXCL12 γ protein (thereafter called γ -wt for the recombinant and chemically synthesized proteins, GenPept NCBI accession number NP_001012495). The expression of the γ -wt mRNA and protein in embryo and adult mouse tissues and in human adult tissues was investigated by RT-PCR and immunohistochemistry (Figure 1C–E) using a novel monoclonal antibody (mAb) (6E9) that recognizes selectively a γ -wt C-ter epitope encompassing the sequence K78/K80 (Figure 1A–B). The γ -wt protein expression was compared to these of other isoforms detected by the well characterized K15C mAb, which recognizes an amino-terminal

(N-ter) -encoded epitope shared by all the CXCL12 isoforms [29,30].

In adult mice, the *Cxcl12 γ* mRNA was poorly expressed in liver, intestine and kidney, contrasting with the abundant expression of *Cxcl12 α* mRNA (Figure 1C). Regarding the protein (Figure 1D), γ -wt was undetectable in bladder muscular and mucosa layers, while in the intestinal tract, a faint and discontinuous immunostaining was restricted to the mucosa and excludes the muscular layer (Figure 1Diii). *Cxcl12 γ* mRNA was abundant in brain, heart (Figure 1C) and bone marrow, where it was expressed as a predominant isoform akin to *Cxcl12 α* as quantified by real time PCR (Figure 1E). γ -wt protein was detected in cardiac muscle, valves and large vessels (Figure 1Di). In lungs, *Cxcl12 γ* mRNA expression was barely detected in the adult (Figure 1C). Interestingly, a detailed analysis of γ -wt expression in mouse embryos showed that while the protein was virtually absent from trachea and large bronchia, it accumulated in the bronchioli (Figure 1Dii). The γ -wt protein was consistently detected in mesothelial tissues such as peritoneum (Figure 1Diii) and pleura (data not shown). Of note, γ -wt was detected in endothelia of large and small vessels both in human and mouse (Figure 1Div–v), and in fibroblasts either of human skin (data not shown) or synovial inflammatory tissue (rheumatoid arthritis; Figure 1Dv).

γ -wt binds to immobilized and cell surface HS with high affinity

Previously it has been shown that the CXCL12 α protein (α -wt) binds with high affinity to HS [31] both *in vitro* and in intact cells through specific interaction with the canonical HS-binding motif (K24H25L26K27) located in the core of the protein shared by all the CXCL12 isoforms. Mutation of this motif (K24S/K27S) fully prevents binding to HS without affecting neither the overall structure nor the capacity of the mutant chemokine (α -m) to bind and activate CXCR4 [31]. The specific C-ter domain of the γ -wt isoform presents a marked basic character, with a 60% of the residues being positively charged and clustered in 4 overlapped HS-binding sites. This prompted us to investigate the γ -wt/GAG interactions both *in vitro* and on intact cells. Analysis performed with chemically synthesized chemokines, showed that γ -wt isoform required 1.01 M NaCl to be eluted from a heparin (HP)-affinity column (Figure 2B) as compared to 0.59 M required for elution of α -wt. Chemically synthesized γ -wt C-ter peptide encompassing amino-acids 69 to 98 of the corresponding γ -wt protein required 0.88 M NaCl to be eluted, indicating that this domain interacts with HP *per se* with high affinity and might contribute to the strong interaction with HP displayed by γ -wt. In good agreement, neutralization of positively charged amino-acids by mutation of the C-ter BBXB motifs either in the γ -wt (γ -m1, Figure 2A) or the isolated C-ter peptides (C-ter γ -m1 and C-ter γ -m2, Figure 2A), reduced drastically the ionic force (0.69, 0.5 and 0.28 M NaCl, respectively, Figure 2B) required for their elution from the HP-affinity column.

Surface plasmon resonance (SPR) experiments (Figure 2C) confirmed that γ -wt interacts with HP with unprecedented high affinity ($K_d = 0.9$ nM). Furthermore, they showed that the interaction with the oligosaccharide was severely impaired in the mutant γ -m1 ($K_d = 10.4$ nM), thus proving the important contribution of the C-ter domain BBXB sites to the binding on HP. Both HP-affinity chromatography and SPR experiments (Figure 2B–C) proved that the γ -m2 mutant (Figure 2A), which lacks all functional BBXB motifs, was virtually devoid of the capacity to interact with HP.

Recognition of CXCL12 proteins by the K15C mAb is not masked by their interaction with GAG [23]. Using this mAb, we




Figure 1. Tissue expression of γ -wt in human and mouse. (A) Specific immunofluorescent detection of γ -wt. HEK-293T cells were transfected either with β -wt- (upper panel) or γ -wt- (lower panel) expressing pCDNA3.1 plasmids, treated with Brefeldin A, permeabilised with saponin and labelled with the 6E9 mAb and a Texas Red anti-mouse IgG. The nuclei of cells were counterstained with DAPI. Images are representative of six independent determinations. Original magnification $\times 63$. (B) Mutagenesis of K78/K80 in γ -wt C9 (γ -C9^{up}) prevents the specific recognition of the γ -wt chemokine by the 6E9 mAb. Western blot analysis of chemically synthesized α -wt and γ -wt (synt) and α -wt C9, γ -wt C9, γ -C9^{up} and γ -C9^{dw} C9-tagged chemokines expressed from SFV-vectors in BHK cells. Cell lysates (L) or culture supernatants (S) were separated by SDS-PAGE and probed with 6E9 mAb and a HRP-sheep anti-mouse Ig secondary antibody. MW, molecular weight in K Dalton. Results are representative of two independent determinations. (C) Expression of *Cxcl12 α* and *Cxcl12 γ* mRNAs by RT-PCR in different adult mouse tissues. β -actin was used as loading control. RT +/- denotes presence or absence of RT enzyme. Data are representative of three independent determinations. (D) Detection of CXCL12 isoforms either with K15C mAb or anti- γ -wt 6E9 mAb in mouse and human tissues. (i) Mouse adult heart. LA, left auricle; LV, left ventricle; RV, right ventricle; IVS, interventricular septum; ca, carotid artery; mv, mitral valve. (ii) Detail of a lung bronchiol (mouse E16.5 embryo). (iii) Mouse E16.5 embryo intestine and bladder. White arrowheads, bladder epithelium; black arrowheads, large intestine; arrows, peritoneum. In inset, details of intestinal mucosa labeling. (iv) Large abdominal vessel (mouse E16.5 embryo). (v) Human inflammatory synovial tissue (rheumatoid arthritis). White arrowheads, blood vessel; black arrowheads, lining synoviocytes; arrows, fibroblasts. Control: secondary antibody. Original magnifications $\times 4$ (i,iii inset), $\times 10$ (ii), $\times 20$ (iv), $\times 40$ (ii) and $\times 400$ (v). (E) CXCL12 expression in the mouse bone marrow. Left panel, expression of *Cxcl12 α* (α) and *Cxcl12 γ* (γ) mRNAs determined by quantitative real time-PCR and normalized to *Gapdh* expression. Results are representative from three independent determinations for each PCR reaction. Right panel, detection of CXCL12 isoforms by use of either K15C or anti- γ -wt 6E9 mAb. Control: secondary antibody. Original magnification ($\times 40$).

doi:10.1371/journal.pone.0002543.g001

observed that the adsorption on the CXCR4 negative CHO-K1 cells was greatly increased for γ -wt as compared to α -wt (Figure 3A). Of note, and of particular biological relevance, we found that γ -wt also binds onto primary, human-microvascular

endothelial cells (HMVEC) with the highest efficiency as compared to α -wt (Figure 3B). It is interesting to note that while the γ -m1 mutant protein retained the capacity to bind on CHO-K1 parental cells, this capacity was notably decreased in HMVEC,




Figure 2. Immobilized GAG-binding activity of γ -wt. (A) Sequence alignment of CXCL12 γ wt (γ -wt), mutated derivatives chemokines (γ -m1 and γ -m2) and mutant CXCL12 γ C-ter peptides (C-Ter γ -m1 and C-Ter γ -m2). In bold, identified and putative HS-binding motifs; underlined, substituted amino acids. (B) Binding to HP-affinity columns of chemically synthesized wt (α -wt, γ -wt) or mutant (α -m, γ -m1, γ -m2) chemokines or peptides encompassing amino acids 69 to 98 of CXCL12 γ wt (C-ter γ -wt) or their mutated derivatives (C-ter γ -m1, C-ter γ -m2). Proteins were applied to heparin Hitrapp-columns and eluted with a 0.15 to 1 M NaCl gradient. Values correspond to the NaCl molar (M) concentration required for elution from the heparin column and represent three independent experiments. (C) Binding of α -wt, γ -wt, γ -m1 or γ -m2 to on chip-immobilized heparin (HP). Chemokines were injected over HP activated surface for 5 min, after which running buffer was injected, and the response in relative units (RU) was recorded as a function of time. Each set of sensorgrams was obtained with α -wt at (from top to bottom) 200 to 0 nM or γ -wt, γ -m1 and γ -m2 at 25 to 0 nM. Results are representative of three independent determinations. doi:10.1371/journal.pone.0002543.g002

a divergence that could be accounted for by differences in the amount and nature of negatively charged structures that contribute to CXCL12 binding in both cell types. Interestingly, a recombinant CXCL12 γ derivative carrying K24S and K27S substitutions (γ -K2427S_r) that invalidate the HS-binding consensus site located in the core of the protein [25] (Figure 3B) also exhibits a reduced capacity to bind on HMVEC cells as compared to the corresponding γ -wt_r protein. In keeping with these results, the γ -m2 was virtually devoid of any binding capacity on both cell types. The specificity of CXCL12 γ binding to GAG was assessed in mutant CHO-pgsD677 cells, derived from CHO-K1 cells, which lack both *N*-acetylglucosaminyltransferase and glucuronyltransferase activities and are deficient for HS synthesis, the binding of γ -m1 became undetectable, whereas a residual signal was still detectable for γ -wt (Figure 3A), and at a similar extent for the γ -K2427S_r (data not shown). Comparable phenomena were observed in CHO-pgsA745 cells, which lack any GAG synthesis due to a xylose-transferase mutation. The residual binding of γ -wt (or γ -K2427S_r) observed at high concentrations of the chemokine (250 nM), in the absence of any synthesized GAG, can be accounted for by the interaction of the C-ter domain with other negatively charged structures, like the abundant sulphate glycosphingolipids (sulphatides) that have been previously shown to interact at high concentrations with α -wt [32]. The enzymatic degradation of HS in CHO-K1 cells either by heparinase or heparitinase I confirmed the apparent selectiveness of the HS/ γ -wt interaction at the cell surface, whereas degradation of chondroitin sulfate had no effect (Figure S1).

Collectively these results demonstrate the hypothesis that both the protein core and C-ter HS-binding sites collaborate to provide CXCL12 γ with the characteristic and unchallenged, high affinity binding for GAG, and prove the validity of this assumption in cell models of biological relevance.

Neosynthesized γ -wt shows an unusual pattern of cell secretion and accumulation

For ease of detection, the sequence coding for a 9 amino acid C-ter (C9-tag) peptide from bovine rhodopsin that has been satisfactorily used for tagging a large number of unrelated proteins, was added in frame at the 3' end of the open reading frames (ORF) of the *Cxcl12 α* - and *Cxcl12 γ* -encoding constructs, giving rise to the α -wt C9 and γ -wt C9 proteins, respectively. Chemokines were expressed in BHK cells by infection with Semliki forest virus (SFV) particles expressing the corresponding C9-tagged isoform. We observed that, upon expression, the γ -wt C9 protein was hardly detectable by western blot analysis in the BHK cell culture supernatants (Figures 1B and 4D). This finding prompted us to investigate the fate of this protein and to compare it to that of α -wt C9 which was engineered and expressed under identical experimental conditions (Figure 4A). Quantification in an ELISA assay showed that similar amounts of γ -wt C9 and α -wt C9 were produced from expressing cells (Figure 4B). Moreover, quantification of either cell-associated (cell lysate) or free chemokines (supernatant) revealed that a larger fraction of γ -wt C9 remained associated to cells as compared to α -wt C9. To further investigate the distribution of the chemokine fraction




Figure 3. Cell surface GAG-binding activity of α -wt and γ -wt. (A) Parental (K1) or GAG-mutant (pgsD677, pgsA745) CHO cells were incubated with the indicated concentration of wt (α -wt, γ -wt) or mutant (γ -m1, γ -m2) chemokines for 60 min at 4°C, and after extensive washing to remove free chemokine, were labelled with K15C mAb and a PE-goat anti-mouse Ig secondary antibody. Fixed cells were analyzed by flow cytometry. Values represent the mean fluorescence intensity \pm SD of three independent experiments performed in triplicate (B) Primary human-microvascular endothelial cells (HMVEC) were incubated with the indicated concentration of chemically synthesized (α -wt, α -m, γ -wt, γ -m1, γ -m2; left) or recombinant (γ -wt_r, γ -K2427S_r, γ -m1_r, right) chemokines and treated as in (A). Values represent the mean fluorescence intensity \pm SD of two independent experiments performed in triplicate. * p <0.05, ** p <0.01, *** p <0.005 as compared to the binding obtained for the corresponding concentration of γ -wt (for γ -m1 and γ -m2) or γ -wt_r (for γ -K2427S_r and γ -m1_r) chemokines. doi:10.1371/journal.pone.0002543.g003

associated to cells, we performed labelling of α -wt C9- and γ -wt C9-expressing cells using the anti-C9 1D4 mAb (Figure 4C). Interestingly, γ -wt C9 markedly amassed at the cell surface in contrast to α -wt C9 (Figure 4C right panel), while in the presence of Brefeldin A, similar amounts of each chemokine accumulated in intracellular stores (Figure 4C left panel). Enzymatic exposure to heparitinase I reduced the intensity of the signal for both chemokines (data not shown), which is in full agreement with the previous SPR data showing that γ -wt binds with exceptionally high affinity to on-chip immobilized HS (Figure 2C) and the results obtained from the enzymatic treatment of CHO-K1 cells (Figure S1). These findings led us to postulate that given the cationic nature of the C-ter of γ -wt and its high affinity for GAG, electrostatic forces enable this chemokine to bind tightly to negatively charged structures at the cell surface. This assumption was tested by shortly exposing SFV-infected BHK cells expressing either γ -wt C9 or α -wt C9 to isotonic PBS or 1 M NaCl solution, in order to disrupt the electrostatic interactions and eventually promote release of the chemokine into the fluid (Figure 4D). Cell viability of NaCl-treated cells was not altered as compared to this of control cells (data not shown) when assessed by blue-trypan dye exclusion. While α -wt C9-expressing cells did not release detectable amounts of this isoform in the wash fluid (Figure 4D lanes 3–4), a significant amount of γ -wt C9 was released upon short exposure of cells to 1 M NaCl solution (Figure 4D lane 9). These findings were reproduced in other cell types (HEK 293T) and with different expression vectors (pcDNA3.1).

γ -wt displays reduced agonist potency on CXCR4 activation as compared to α -wt

The pharmacological properties of γ -wt regarding its interaction with CXCR4 were investigated on transformed A3.01 T cells and primary unstimulated CD4⁺ T lymphocytes (Figure 5). Both lymphoid cell types lack detectable levels of HS as assessed by immunostaining with the specific 10E4 anti-HS mAb (data not shown) and permits the strict analysis of CXCL12/CXCR4 interaction *per se*. The capacity of γ -wt to set in motion CXCR4-dependent activation cell pathways was first assessed by measuring the amount of the non-hydrolysable [³⁵S]-GTP γ associated to activated G α subunits, the earliest cell-signal event induced by GPCR agonists. We observed that γ -wt was less potent than α -wt to activate CXCR4 (Figure 5A), which is in full agreement with the reduced binding affinity (one order of magnitude) shown by γ -wt for CXCR4 as compared to α -wt [28]. When concentration of γ -wt was raised and the occupancy of CXCR4 was enhanced, G protein activation increased to levels comparable to those measured with α -wt. However, presumably due to the sustained reduced potency of γ -wt to induce GTP γ S binding, we were unable to reach saturation for γ -wt, thus precluding determination of E_{max} and EC_{50} values for this chemokine in this assay. For α -wt isoform, we deduced an EC_{50} value equal to 19.65 nM. CXCL12 α has been shown to bind to- and activates CXCR7 [3,4,33]. We thus analysed the ability of γ -wt to compete with a C-ter biotinylated CXCL12 α chemokine for binding to CXCR7. As shown in Figure S2, α -wt and γ -wt isoforms similarly bound to




Figure 4. Electrophoretic mobility and secretion pattern of γ -wt and α -wt chemokines. (A) For detection of CXCL12 proteins by immunoblot, SFV-infected BHK cell lysates were separated by SDS-PAGE and probed with the K15C mAb and a HRP-sheep anti-mouse Ig secondary antibody. Abbreviations like in Fig. 1B. Formation of dimeric forms are observed for α -wt synt, α -wt C9, γ -wt synt and γ -wt C9. Results are representative of three independent determinations. (B) ELISA quantification of α -wt C9 and γ -wt C9 expressed by HEK-293T cells transfected with the corresponding pcDNA3.1 expression vector. Total protein or chemokine accumulated in the cell supernatant (S) or in the cell lysates (L) were determined. The values (ng/ml) are mean \pm SD from triplicate measurements. ** $p < 0.005$, *** $p < 0.0005$. (C) The secreted γ -wt C9 protein revealed by the anti-C9 1D4 mAb accumulates massively at the cell surface of HEK-293T cells treated like in (B), and permeabilised (left panel) or not (right panel) with saponin. In inset, cell surface CXCR4 expression of HEK-293T cells. Results are representative of four independent determinations. (D) The γ -wt C9 chemokine is released from intact cells upon exposure to strong ionic force. BHK cells were infected with SFV-infectious particles driving the expression either of α -wt C9 or γ -wt C9. Thereafter, the proteins were detected by western blot analysis using the anti-C9 1D4 mAb in the cell culture supernatant (S), the wash fluid (WF) or the cell lysate (L), upon a 5 min exposure of cells either to PBS or hypertonic NaCl 1 M (NaCl). Results are representative of four independent determinations.
doi:10.1371/journal.pone.0002543.g004

CXCR7 ($IC_{50} = 6.56$ nM and 10.37 nM for α -wt and γ -wt, respectively).

We next investigated the capacity of γ -wt to promote CXCR4-mediated lymphocyte migration, the hallmark of chemokine-promoted responses (Figure 5B). Addition of γ -wt to A3.01 cells (upper panel) or primary CD4⁺ T lymphocytes (lower panel) confirmed, in agreement with previous findings [33], the reduced potency of γ -wt as compared to α -wt regarding chemotactic activity. Addition of the specific CXCR4 antagonist AMD3100 resulted in the blockade of both G-protein coupling and cell migration, thus proving the specificity of CXCR4/ γ -wt interactions (Figure S3).

Inactivation of the C-ter BBXB motifs in γ -wt (γ -m1 and γ -m2) restored the potency of the chemokine to the levels showed by α -wt and α -m, two chemokines that have been previously shown to bind to and activate CXCR4 similarly [31]. Comparable results were found regarding GTP γ S binding, as the γ -m1 mutant proved to be consistently a better agonist than γ -wt, displaying a similar potency than this observed for α -wt (data not shown). Additionally, these findings indicated that the mutations introduced in the C-ter domain did not affect the overall structure of the chemokine. The biological relevance of these results was further confirmed in human blood leukocytes activated with phytohemagglutinin and IL-2, a process known to enhance GAG expression on primary cells [34] (Figure S4).

In vivo biological activity of γ -wt

The singular structural and functional features that distinguish γ -wt from α -wt prompted us to compare their respective capacities

to promote haptotactic attraction of cells *in vivo* using chemokine concentrations in the range of these that consistently induce chemotaxis *in vitro*. To this purpose, we first evaluated the migration of leukocytes into the peritoneal cavity of BALB/c mice following administration of an endotoxin-free, 30 nM solution, of γ -wt or α -wt at 6 hours (hr) (Figure 6A) or 15 hr (Figure 6B) post-injection. After 6 hr of treatment, both α -wt and γ -wt induced a significant and equivalent increase of the absolute number of cells (fold increase 2.99 ± 0.18 and 3 ± 0.18 , for α -wt and γ -wt respectively, as compared to control PBS injected animals), that was accounted for by the recruitment of myeloid cells, including both neutrophils and macrophages (Gr-1+CD11b+CD19-, 6.27 ± 1.45 for α -wt and 8.72 ± 4.95 for γ -wt). The situation was radically different at 15 hr post-injection as solely γ -wt promoted a sustained accumulation of leukocytes (fold increase 4.96 ± 1.35 as compared to PBS-injected animals). At this time point, cell increase was basically accounted for by T lymphocytes (CD3+, 4.38 ± 1.65) and B lymphocytes corresponding to B1 (CD19+CD11b+, 5.09 ± 2.16) and B2 (CD19+CD11b-, 3.9 ± 1) subpopulations. Importantly, both α -m and γ -m2, that totally lack HS-binding activity, failed to attract leukocytes either at 6 hr or 15 hr time points.

CXCL12 α has the capacity to promote *de novo* formation of vessels, a property related to the ability of this chemokine to regulate both the traffic and survival of stem and progenitor cells [19,35]. Thus, we compared the ability of γ -wt and α -wt to attract endothelial progenitors and initiate the angiogenic process. To this purpose, Matrigel plugs loaded with an endotoxin-free, 10 nM




Figure 5. Cell signalling through CXCR4 induced either by α -wt, γ -wt or derivative chemokines. (A) CXCL12-induced [^{35}S]GTP γ S binding to membranes from lymphoblastoid A3.01 T cells. Membranes were incubated in assay buffer containing 0.1 nM [^{35}S]GTP γ S and the indicated concentrations of the corresponding chemokine. Data represents the percentage (mean \pm SD) of the maximal [^{35}S]GTP γ S binding obtained (100%), and are representative of three independent experiments. (B) Dose-dependent CXCL12-induced chemotaxis of A3.01 cells (upper panel) or primary CD4 $^{+}$ T lymphocytes (lower panel). Results (mean \pm SD) are from two independent experiments and are expressed as percentage of input cells that migrated to the lower chamber.

doi:10.1371/journal.pone.0002543.g005

solution of either γ -wt or α -wt were implanted subcutaneously in BALB/c mice. Whereas virtually no infiltrating cells were detectable in control PBS Matrigel plugs (data not shown), γ -wt induced a more robust response (3-fold increase, $p = 0.0009$ Figure 7A) than α -wt regarding the total number of cells attracted at day 10 post-implantation. Vessel-like cellular tubes within Matrigel implants were particularly abundant in γ -wt-loaded implants. These vessel-like structures were mainly composed of endothelial cells expressing CD31/Platelet endothelial cell adhesion molecule (PECAM-1) (Figure 7B), a molecule that defines endothelial cells. Similar results were observed 6 days post-implantation, the minimal time-point required to observe angiogenesis using this technique [36] ($p = 0.0459$, Figure 7A table). Of note, both α -m and γ -m2 display a reduced capacity to promote cell infiltration and angiogenesis in Matrigel implants, demonstrating the importance of GAG binding for this process.

Discussion

Cxcl12 γ mRNA has been primarily detected in the central nervous system of adult rats, where this isoform is supposed to undergo inverse regulation as compared to the β isoform both during brain development and in pathophysiological events like sciatic nerve lesion [26]. *Cxcl12 γ* mRNA is also differentially expressed in normal and myocardial infarcted rat heart [37], in normal and ischemic brain of mice [38], and is broadly detected in human adult tissues [27]. Here, we have characterized for the first time the expression of CXCL12 γ at the protein level. The apparent exclusion of both *Cxcl12 γ* mRNA and protein from discrete places suggests that the expression of this isoform is tightly regulated by a RNA-splicing regulatory mechanism. Remarkably, CXCL12 γ seems to be expressed in anatomical sites, such as small vessels and lower respiratory tract, where it could be involved in the diapedesis of inflammatory leukocytes and other cells from hematopoietic origin. In embryo, its enhanced capacity to form haptotactic gradients could be critical for guiding discrete cell precursors into their final localization during organogenesis.

The tight array of BBXB motifs in the CXCL12 γ C-ter domain, that distinguish this protein from other CXCL12 isoforms, is unprecedented among HS-binding proteins. The C-ter domain has on its own a marked affinity for heparin that decreases dramatically when HS-binding motifs are mutated. This observation is in keeping with our results issued from a Nuclear Magnetic Resonance analysis of the soluble form of this chemokine [28], which revealed that the C-ter peptide is unfolded and could offer an accessible, highly cationic surface for the molecular recognition in the interaction with GAG. Our interpretation of SPR findings is that the high affinity for the oligosaccharide displayed by γ -wt largely relies in the low k_{off} of the HP/ γ -wt complexes which has been estimated to be $0.0019 \text{ M}^{-1} \text{ s}^{-1}$, contrasting with the rapid dissociation from HP observed for α -wt ($k_{\text{off}} 0.111 \text{ M}^{-1} \text{ s}^{-1}$) [28]. This is well exemplified by the SPR profile obtained with the mutant γ -m1. This mutant dissociates more rapidly from HP and shows a marked, reduced interaction with HP as compared to the wild type counterpart. However, it retains a substantial affinity for HP that might result from the stabilization of the complex through the collaboration between the conserved BBXB motif in the core of the chemokine and the remaining positive charges in the yet highly cationic C-ter domain. Collectively, these data underline the important contribution of the C-ter BBXB motifs to the formation of high-affinity and stable HP/ γ -wt complexes.

The chemokine-binding experiments carried out in intact cells proved the specificity and high affinity of γ -wt for cellular HS structures, thus validating the biological relevance of the *in vitro*




Figure 6. Intraperitoneal recruitment of leukocytes induced by α -wt and γ -wt. BALB/c mice were intraperitoneally injected with identical volumes (300 μ l) of either PBS (control) or a 30 nM solution of each chemokine. Cells that accumulated into the peritoneal cavity were recovered after 6 hr (A) or 15 hr (B) of treatment. Leukocyte subpopulations were characterized by flow cytometry using specific cell markers. Cell influx was calculated as the x-fold increase over values obtained in PBS-treated mice. PBS reference values were arbitrary set to one (dotted lines). In inset, total number of recovered peritoneal cells. Results are mean \pm SD of three independent experiments. * p <0.05, ** p <0.01, *** p <0.005 as compared to PBS-treated mice.

doi:10.1371/journal.pone.0002543.g006

analysis. The astounding strong interaction of γ -wt with cell GAG was also observed in an alternative assay. Indeed, our findings prove that γ -wt is massively adsorbed at the cell surface following secretion. The simplest explanation for this phenomenon is that the secreted γ -wt could be rapidly trapped on cell-surface HS structures. Alternatively, the high affinity of γ -wt for HS might result in the formation of an intracellular complex before being expressed at the cell surface, a phenomenon previously described for the Fibroblast Growth Factor-2 [39]. On view of the low dissociation rate of HS- γ -wt complexes, it can be speculated that the secreted, free form of the chemokine hardly would reach the equilibrium of interaction with immobilized HS and that under physiological conditions, the binding of natural CXCL12 γ to extracellular HS structures is tight and long-lasting.

Using lymphoid T cells, we confirm that γ -wt signals through CXCR4 with diminished agonist potency as compared to α -wt. This can be accounted for by the decreased affinity of γ -wt for CXCR4 that was previously reported [28]. It can be hypothesized that, either the electrostatic interactions of the highly cationic C-ter domain with the negatively charged N-ter domain and extracellular loops of CXCR4 [40], or the steric hindrance promoted by the bulky basic residues in the γ -wt C-ter domain, impair the specific interaction with CXCR4 and therefore reduce the agonist potency of γ -wt.

Importantly, neutralization of positive charges in the BBXB motifs of γ -wt (γ -m1 and γ -m2) leads to an increased affinity for [28] and activation of CXCR4 comparable to this achieved either by α -wt or α -m, two proteins that preserves similar overstructure and efficiency towards CXCR4 [31]. Collectively, these findings conclusively identify the charged C-ter domain as responsible for the distinctive structural and cell-signaling properties showed by γ -wt. In contrast to the situation observed for CXCR4, γ -wt binding to CXCR7 is comparable to this of α -wt, suggesting that molecular determinants of CXCL12 for binding to CXCR4 and CXCR7 are different.

The demonstration of *in vivo* consequences of chemokine/GAG interactions have been hampered by conformational changes

consecutive to the mutagenesis of BBXB consensus sites that leads frequently to an overall reduced affinity of the chemokine for the corresponding receptor [22]. The naturally occurring CXCL12 γ protein is free of this bias and offers an unprecedented opportunity to ascertain the importance of chemokine/GAG complexing in the regulation of *in vivo* cell migration in adult life.

The capacity of endogenous CXCL12 α to promote leukocyte attraction in the peritoneum has been proved previously [41]. Similarly, it has been demonstrated that the formation of vessels under physiological [19] and pathological conditions [35] is induced by CXCL12 α and is related to the regulation of the traffic and survival of CD34+ progenitor cells. The secreted signalling protein Vascular Endothelial Growth Factor-A (VEGF-A) is another potent and specific angiogenic factor [42]. *Vegf-A* isoforms are produced by alternative splicing from a single gene [43] and their levels are exquisitely regulated through transcriptional control and mRNA stability [44]. Similarly to CXCL12, these isoforms differ by the absence or presence of protein domains that confer the ability to bind heparin and therefore could mediate their capacity to interact differentially with GAG components in the extracellular environment of VEGF-secreting cells [45]. In keeping with this assumption, it has been shown that the absence of the heparin-binding isoforms of VEGF-A alters the distribution and gradients of VEGF-A protein without heparin-binding capacity in tissues and leads to a reduced vascular branching complexity and increased microvessel calibre [46]. This situation is reminiscent of our observation showing that γ -wt displays an enhanced capacity to induce *in vivo* recruitment of cells as compared to α -wt, which is due to its enhanced affinity for HS. This conclusion is strongly supported by the fact that the HS-binding disabled mutant γ -m2 is devoid of detectable activity *in vivo* despite it shows full agonist potency on CXCR4 *in vitro*.

It has been shown that the association of HS with CXCL12 α prevents the proteolytic attack of its N-ter domain by the endopeptidase CD26/DPP, thus preserving the functionality of the chemokine [23]. CXCL12 γ encodes several serine-protease




Figure 7. Angiogenic effect of α -wt or γ -wt and derivatives chemokines. (A) Haematoxylin-eosin staining of Matrigel plugs containing 10 nM of the indicated chemokine and analyzed at day 10 from implantation in BALB/c mice. Data are representative of ten independent experiments. In frame, vessel-like structures forming around a central lumen. In the table, quantification of the number of migrated cells (\pm SD) into the Matrigel after 6 ($p=0.0459$) or ten days ($p=0.0009$) from implantation. (B) Immunofluorescent detection of PECAM-1/CD31⁺ endothelial cells in Matrigel neovessels with DAPI nuclear counter-labelling. Original magnifications $\times 100$ (A) and $\times 600$ (B).
doi:10.1371/journal.pone.0002543.g007

cleavage sites in its distinctive C-ter and is conceivable that, like for VEGF-A [47], the interaction of γ -wt with HS also protects this domain from proteolytic attack, thus contributing to the prolonged immobilization and increased half-life of CXCL12 γ in tissues.

Overall, from our findings, we conclude that, despite its reduced agonist potency on CXCR4, both the prolonged immobilization and increased stability of γ -wt would determine the superior capacity of this isoform to promote chemotaxis *in vivo* as compared to α -wt.

The conserved structure and differential expression of CXCL12 γ both during development and in homeostatic and pathological conditions in the adult, herald the important and specific role that it might play both in embryogenesis and in adult life. Its localization in vascular endothelia where leukocyte diapedesis occurs and pathogen host defense are initiated, suggests that this chemokine is key in the fine-tuning of immune responses. CXCL12 γ would represent the paradigm of haptotactic proteins that critically promote the directional migration and tissue homing of cells and regulate important homeostatic and physiopathological functions.

Materials and Methods

Chemokine synthesis and monoclonal antibodies

Chemically synthesized peptides and chemokines were generated by the Merrifield solid-phase method, and evaluated for their purity and concentration by mass spectrometry and amino-acid hydrolysis, respectively, as described [31]. The endotoxin content of the protein stocks (100 μ M) was determined using a highly sensitive Limulus test (Limulus Amebocyte Lysate kit, Cambrex). Recombinant, wild type (γ -wt_r) or mutant (γ -m1, and γ -K2427S_r) CXCL12 γ chemokines were also obtained from *E. coli* BL21 cells by using the pET17b expression vector, analysed by mass spectrometry and quantified by amino acids analysis as described [28]. The 6E9 mAb (IgG1 κ) directed against the wild type CXCL12 γ protein was generated by immunizing BALB/c mice with a linear peptide containing the last 30 amino-acids of the γ -wt mature isoform, as previously described [31]. The mAb clone K15C was generated against an N-ter peptide shared by all the CXCL12 isoforms [31].

Heparin affinity chromatography and SPR-based binding assays

Heparin affinity chromatography of chemokines was performed as previously described [48] on a 1-ml Hitrap heparin column and submitted to gradient elution from 0.15 to 1 M NaCl in 20 mM Na₂HPO₄/NaH₂PO₄. For SPR experiments, size defined HP (6 kDa) was biotinylated at its reducing end and immobilized on a Biacore sensorchip as described [48]. For binding assays, 250 μ l of chemokine solution (26, 39, 59, 89, 133 or 200 nM for α -wt and 3.3, 4.9, 7.4, 11, 16.6 and 25 for γ -wt, γ -m1 and γ -m2) was injected at a flow rate of 50 μ l/min across control and HP surfaces, after which the formed complexes were washed with running buffer for 5 min. The sensorchip surface was regenerated with a 3 minutes pulse of 2 M NaCl. Control sensorgrams were subtracted on line from HP sensorgrams. Equilibrium data were extracted from the sensorgrams at the end of each injection and K_d were calculated using the Scatchard representation.

Cloning of Cxcl12 isoforms

Brain tissue was obtained by dissection of a BALB/c adult mouse. Total RNA was obtained by using the Trizol reagent (Roche, Basel, Switzerland) and after phenol-chloroform purification, isopropanol precipitation and quantization, cDNA was synthesized using 1 μ g of total RNA. *Cxcl12 α* , β and γ cDNA sequences were amplified using the common forward primer 5'atattgcgcgatggagccaaggtcgtcgcc3' and the isoform specific reverse primers 5'tacctggagaagccttaaaccaagtaaggcccaatat3' for *Cxcl12 α* , 5'gctttaacaagaggctcaagatgtgaggcccaatat3' for *Cxcl12 β* , and 5'cgacagaagaagagaaggctgccagaaaaggaaaactagggcccaatat3' for *Cxcl12 γ* . Amplified sequences were subcloned in a pcDNA3.1 expression vector or in a plasmid containing the SFV genome deleted for structural genes (pSFV-1). For ease of detection, the sequence coding for the bovine rhodopsin C9-tag (TETSQVAPA) was added in frame at the 3' end of the open reading frames (ORF) of the *Cxcl12 α* - and *Cxcl12 γ* -encoding constructs, giving rise to the α -wt C9 and γ -wt C9 proteins, respectively. Nucleotide substitution (serine-coding triplets) in the *Cxcl12 γ* -C9 construct corresponding to K78/K80 or R86/K88 gave origin to the γ -C9^{HP} and γ -C9^{dw} proteins, respectively.

Expression of Cxcl12 isoforms

Production of defective SFV particles and infections were performed as described [49]. pcDNA3.1 constructs were transfected in HEK-293T cells by the calcium phosphate method.

Culture supernatants from 18 hours (hr)-SFV infected or 48 hr-transfected cells were collected and cleared by centrifugation. For preparing cell lysates, cells were detached in PBS-EDTA, centrifuged and pellets were treated with lysis buffer (20 mM Tris pH 7.5, 100 mM (NH₄)₂ SO₄, 10% Glycerol, 1 \times protease inhibitor and 1% Triton X-100) and thereafter, cleared by centrifugation. In some experiments, cells were washed for 5 minutes at 4°C with PBS or 1 M NaCl solution prior to cell lysis and centrifuged before collecting wash fluids.

RT-PCR

Total cDNA from tissues was obtained as described above. The PCR reaction was carried out using the forward primer 5'tgccttcagattgttgac3', common for all isoforms, and the isoform specific reverse primers 5'gctaactggttaggtaatac3', 5'cttgagcctctgtttaa3', and 5'gctagctacaagcgccagagcagagcgcactgcg3' for *Cxcl12 α* , *Cxcl12 β* and *Cxcl12 γ* , respectively. β -actin, amplified using the forward 5'acactgtgccatctagcagggg3' and reverse 5'atgatggagttgaaggtattctgtgat3' primers, was used as a loading control.

Quantitative real time-PCR was performed in Mx3005Tm QPCR System with a MxPro QPCR Software 3.00 (Stratagene, La Jolla, CA) and SYBR Green detection system. Forward and reverse primer pairs, designed using online Primer3 software Primer3input (primer3 www. Cgi v 0.2), were 5'cttcaccctctctca3' and 5'gactctgctctggtggaagg3' for *Cxcl12 α* and 5'cgcttgaactcgctctc3' and 5'cagggcctatgaagcacat3' for *Cxcl12 γ* . No amplification was observed in PCR control reactions containing only water as the template. The Livak method was used to analyze the relative quantification RT-PCR data.

Immunoblotting

For immunoblotting analysis, samples were separated on 4–12% SDS-PAGE (Bio-Rad, Hercules, CA), transferred to Filter type PDVF sequencing membrane (Millipore, Billerica, MA) and probed either with the anti-C9 (1D4), K15C or 6E9 mAb. A HRP-sheep anti-mouse Ig was used as secondary antibody (Amersham, Buckinghamshire, UK). Immunodetection was visualized using a Super Signal West Pico chemiluminescent substrate Kit (PIERCE, Rockford, IL) and a Fujifim LAS-1000 apparatus.

Immunohistochemistry

Paraffin-embedded, mouse tissue sections were deparaffinized and rehydrated through graded alcohols, rinsed with PBS, blocked with a TENG-T solution, and incubated overnight at 4°C with primary K15C, 6E9 mAb or buffer alone (control). Sections were then washed and incubated with an anti-IgG mouse alkaline phosphatase (1/200) for 1.5 hr. Immunostaining was revealed using NBT/BCIP as substrate. Human tissue immunostaining was revealed with an anti-IgG mouse biotinylated antibody and avidin-peroxidase system. Images were acquired using a Nikon Eclipse 80i microscope and a Nikon Digital Sight DS-L camera and software.

Immunofluorescence detection of CXCL12 γ

HEK-293T cells were transfected by the calcium phosphate method with 500 ng of the corresponding pcDNA3.1 expression construct, using the pcDNA3.1 insertless vector as a control and thereafter, cells were spread on polylysine-treated coverslips. Immunofluorescence was performed 48 hr after transfection. To promote intracellular accumulation of CXCL12, cells were treated with Brefeldin A (10 μ g/ml) for the last 4 hr of culture. Cells were washed and fixed with 3.7% paraformaldehyde in PBS, permeabilized with PBS 0.2% BSA, 0.05% Saponine buffer for 30 min at 4°C, incubated with the 6E9 mAb for 30 min at 4°C, and finally

incubated with Texas Red anti-mouse IgG secondary antibody (Vector Laboratories, Burlingame, CA). Images were taken using an inverted microscope Zeiss Axiovert 200 M piloted by Zeiss Axiovision 4.4 software and acquired with a CCD camera Roper Scientific Coolsnap HQ and analysed using the AxioVision LE program.

Flow cytometry analysis

CXCL12 binding to cells. Adherent HEK-293T cells, Human Microvascular Endothelial Cells (HMVEC), parental CHO-K1 cells, HS-deficient CHO-pgsD677 or GAG-deficient CHO-pgsA745 mutant cells were incubated with the indicated concentration of chemokine for 60 min at 4°C. Unbound chemokine was removed by washing and cell-bound chemokine was detected with the K15C mAb. After washing, cells were stained with a PE-goat anti-mouse Ig secondary antibody (BD Pharmingen, San Jose, CA), fixed in 3% formaldehyde buffer and analyzed by flow cytometry (FACSscan, Becton Dickinson, CA). Statistical analyses of the differences in binding between the wild type proteins and their mutant counterparts were conducted using the Prism 5.0 software by fitting an unpaired two-tailed Student's t test.

CXCL12 γ -C9 and CXCL12 α -C9 distribution. Adherent HEK-293T cells were transfected with the corresponding pCDNA3.1 construct by the calcium phosphate method and cultured for 48 hr. Four hours before collecting them, the cell supernatants were removed and, when indicated, Brefeldin A was added to the fresh medium. Collected cells were left untreated or permeabilised with saponin and immunolabelled with the 1D4 mAb and a PE-goat anti-mouse Ig secondary antibody and analysed by flow cytometry. CXCR4 detection was performed using the PE-mouse anti-human CD184 (clone 12G5, all from BD Bioscience).

Enzyme-linked immunosorbent assay.

Quantification of chemokines was carried out using the DuoSet ELISA Development kit for mouse CXCL12 (R&D Systems, MN, USA). Statistical analyses were conducted using the Prism 5.0 software by fitting an unpaired two-tailed Student's t test.

Functional assays

For G-protein activation assay, preparation of crude membrane fractions and [³⁵S]GT γ S binding were performed as described [50]. Data were analysed using non-linear regression applied to a sigmoidal dose-response model (variable slope) with the Prism 5.0 program (GraphPad Software Inc., San Diego, CA). For chemotaxis, freshly isolated CD4+ cells were obtained as described previously [51]. Migration of the lymphoblastoid cell line A3.01 or human primary CD4+ cells in response to CXCL12 was evaluated using a transwell system as described [52].

Intraperitoneal recruitment assay

Two-month-old female BALB/c mice were intraperitoneally injected either with PBS alone (control) or the corresponding chemokine diluted in 300 μ l of PBS at a concentration of 30 nM. Cells were recovered by washing the peritoneum with 20 ml of sterile PBS. Total number of cells per mouse was determined by trypan blue exclusion and they were phenotyped by flow cytometry analysis using the mAbs FITC-rat anti-mouse Gr-1, FITC-hamster anti-mouse CD3, PE-rat anti-mouse CD11b or APC-rat anti-mouse CD19 (all from BD Biosciences). Statistical analyses and model fitting of the effect of the wild type proteins and their mutant counterparts were conducted using the Prism 5.0 software by fitting an unpaired two-tailed Student's t test.

Angiogenesis assay

Mouse subcutaneous Matrigel implants (BD Biosciences) were used as described [53]. Briefly, 500 μ l of Matrigel containing 10 nM concentration of chemokines were subcutaneously injected in the back skin of female 2-mo-old BALB/c mice. The major component of Matrigel is laminin, followed by collagen IV, heparan sulfate proteoglycans, and entactin [54]. After 6 or 10 days, skin containing Matrigel plugs were excised. Frozen sections were fixed in 4% paraformaldehyde and analysed by haematoxylin-eosin staining or immunofluorescent labeling with an anti-CD31/PECAM-1 mAb (Santa Cruz, Ca, USA). Quantitative data were obtained by counting the number of cells (DAPI positive nuclei) per Matrigel area in digitalised images using ImageJ software (<http://rsb.info.nih.gov/ij>). Images were taken in a Zeiss Axioplan 2 microscope (Carl Zeiss, Jena, Germany) using a SpotRT CCD camera and Spot 4.5 software (Diagnostic Instruments, Sterling Heights, MI). Statistical analysis was conducted by fitting an unpaired two-tailed Student's *t* test, as described above.

Supporting Information

Figure S1 Comparative GAG-binding activity of α -wt and γ -wt on parental CHO-K1 cells. Prior to incubation with the proteins, cells were treated with 10–3 units/mL of Heparinase (25°C), Heparitinase I (37°C) or Chondroitinase ABC (37°C) degrading enzymes (Seikagaku corporation, Tokyo, Japan) for 90 minutes. Cells were washed twice with PBS, detached with 2 mM EDTA in PBS and then assayed for CXCL12 binding as described previously (flow cytometry analysis). Binding to control untreated cells were arbitrary set to 100 and binding observed for enzyme-treated cells was expressed as a function of signal obtained in control conditions. Data are the mean \pm SD from three independent determinations. In inset, HS detection at the cell surface of control (K1) or Heparitinase I treated (K1+HT) CHO parental cells was performed using mouse IgM isotype control (gray-filled histogram) or the anti-HS mAb clone 10E4 and a PE-goat anti-mouse Ig secondary antibody.

Found at: doi:10.1371/journal.pone.0002543.s001 (1.59 MB TIF)

Figure S2 CXCR7 is a high affinity receptor for both α -wt and γ -wt. (A) Specific CXCL12 α -CXCR7 interaction. 0.5 nM α -biot was added to A0.01 parental cells (Parental) or CXCR7-transduced A0.01 cells (CXCR7) and revealed by flow cytometry after addition of the streptavidin (SAv)-PE conjugate antibody (BD Bioscience) at 1 μ g/ml. When indicated, α -biot binding to CXCR7 was inhibited using the mouse anti-human CXCR7 mAb (9C4, 50 μ g/ml) or the α -wt chemokine (1 μ M). Binding of SAv-PE alone to parental cells was arbitrary set to 1. (B) Concentration-dependent inhibition of 1 nM α -biot binding to CXCR7-transduced A0.01 cells by untagged α -wt or γ -wt

References

1. Tashiro K, Tada H, Heilker R, Shirozu M, Nakano T, et al. (1993) Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins. *Science* 261: 600–603.
2. Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, et al. (1996) The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. *Nature* 382: 829–833.
3. Balabanian K, Lagane B, Infantino S, Chow KY, Harriague J, et al. (2005) The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. *J Biol Chem* 280: 35760–35766.
4. Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, et al. (2006) A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. *J Exp Med* 203: 2201–2213.
5. Miao Z, Luker KE, Summers BC, Berahovich R, Bhojani MS, et al. (2007) CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is

expressed on tumor-associated vasculature. *Proc Natl Acad Sci U S A* 104: 15735–15740.

6. Shirozu M, Nakano T, Inazawa J, Tashiro K, Tada H, et al. (1995) Structure and chromosomal localization of the human stromal cell-derived factor 1 (SDF1) gene. *Genomics* 28: 495–500.

7. Nagasawa T, Tachibana K, Kishimoto T (1998) A novel CXC chemokine PBSF/SDF-1 and its receptor CXCR4: their functions in development, hematopoiesis and HIV infection. *Semin Immunol* 10: 179–185.

8. Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR (1998) Function of the chemokine receptor CXCR4 in hematopoiesis and in cerebellar development. *Nature* 393: 595–599.

9. Klein RS, Rubin JB, Gibson HD, DeHaan EN, Alvarez-Hernandez X, et al. (2001) SDF-1 α induces chemotaxis and enhances Sonic hedgehog-induced proliferation of cerebellar granule cells. *Development* 128: 1971–1981.

chemokines. Cells were incubated with the indicated concentration of the chemokines, and after washing, labeled with 1 μ g/ml of SAv-PE and analyzed by flow cytometry. Results are normalized for specific binding performed in the absence of competitor (100%, untreated). Binding parameters were determined with the Prism Software using non-linear regressions applied to one-site models. Results (mean \pm SD) are representative out of two (A) or three (B) independent experiments performed in duplicate.

Found at: doi:10.1371/journal.pone.0002543.s002 (1.57 MB TIF)

Figure S3 AMD3100 effect in CXCL12-induced signalling. (A) [³⁵S]GTP γ S binding assay to membranes from lymphoblastoid A3.01 T cells upon activation with increasing concentrations of α -wt or γ -wt chemokines. When indicated 200 nM of AMD3100 was added to the incubation mix. Data are mean \pm SD of triplicate determinations from two independent experiments. (B) Chemotaxis of A3.01 cells. Chemokines were added to the lower chamber at a concentration of 3 nM for α -wt and 10 nM for γ -wt to obtain the maximal chemotactic effect for these cells. When indicated, AMD3100 was added to the upper and lower chamber at a final concentration of 200 nM. Results (mean \pm SD) are from two independent experiments and are expressed as percentage of input cells that migrated to the lower chamber.

Found at: doi:10.1371/journal.pone.0002543.s003 (1.08 MB DOC)

Figure S4 Chemotactic activities of CXCL12 isoforms in activated leukocytes. (A) Primary lymphocytes blasted with phytohemagglutinin and expanded with IL-2 were left untreated or treated with Heparitinase I+Chondroitinase ABC (HT+CH) and incubated with the indicated concentrations of chemokine for 60 min at 4°C. After extensive washing to remove unbound chemokine, cells were labelled with the K15C mAb and a PE-goat anti-mouse Ig secondary antibody. Fixed cells were analyzed by flow cytometry. Values represent the mean fluorescence intensity \pm SD of three independent experiments performed in triplicate. (B) Dose-dependent α -wt- or γ -wt-induced chemotaxis assessed in untreated and HT+CH-treated, activated primary lymphocytes. Results (mean \pm SD) are from two independent experiments and are expressed as percentage of input cells that migrated to the lower chamber.

Found at: doi:10.1371/journal.pone.0002543.s004 (1.33 MB TIF)

Author Contributions

Conceived and designed the experiments: FA HL PR KB JP. Performed the experiments: CL RS PR KB IS KC AL EI EL BL. Analyzed the data: FA HL PR KB JP AC DF BL. Contributed reagents/materials/analysis tools: FB TD. Wrote the paper: FA HL PR KB.

10. Ma Q, Jones D, Borghesani PR, Segal RA, Nagasawa T, et al. (1998) Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. *Proc Natl Acad Sci U S A* 95: 9448–9453.
11. Ara T, Nakamura Y, Egawa T, Sugiyama T, Abe K, et al. (2003) Impaired colonization of the gonads by primordial germ cells in mice lacking a chemokine, stromal cell-derived factor-1 (SDF-1). *Proc Natl Acad Sci U S A* 100: 5319–5323.
12. Shamri R, Grabovsky V, Gauguet JM, Feigelson S, Mancovich E, et al. (2005) Lymphocyte arrest requires instantaneous induction of an extended LFA-1 conformation mediated by endothelium-bound chemokines. *Nat Immunol* 6: 497–506.
13. Kantele JM, Kurk S, Jutila MA (2000) Effects of continuous exposure to stromal cell-derived factor-1 alpha on T cell rolling and tight adhesion to monolayers of activated endothelial cells. *J Immunol* 164: 5035–5040.
14. Grabovsky V, Feigelson S, Chen C, Bleijs DA, Peled A, et al. (2000) Subsecond induction of alpha4 integrin clustering by immobilized chemokines stimulates leukocyte tethering and rolling on endothelial vascular cell adhesion molecule 1 under flow conditions. *J Exp Med* 192: 495–506.
15. Campbell JJ, Hedrick J, Zlotnik A, Siani MA, Thompson DA, et al. (1998) Chemokines and the arrest of lymphocytes rolling under flow conditions. *Science* 279: 381–384.
16. Aiuti A, Webb IJ, Bleul C, Springer T, Gutierrez-Ramos JC (1997) The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. *J Exp Med* 185: 111–120.
17. Nanki T, Hayashida K, El-Gabalawy HS, Suson S, Shi K, et al. (2000) Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4+ T cell accumulation in rheumatoid arthritis synovium. *J Immunol* 165: 6590–6598.
18. Gallagher KA, Liu ZJ, Xiao M, Chen H, Goldstein LJ, et al. (2007) Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1 alpha. *J Clin Invest* 117: 1249–1259.
19. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, et al. (2004) Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. *Nat Med* 10: 858–864.
20. Burger JA, Kipps TJ (2006) CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. *Blood* 107: 1761–1767.
21. Esko JD, Selleck SB (2002) Order out of chaos: assembly of ligand binding sites in heparan sulfate. *Annu Rev Biochem* 71: 435–471.
22. Proudfoot AE, Handel TM, Johnson Z, Lau EK, LiWang P, et al. (2003) Glycosaminoglycan binding and oligomerization are essential for the *in vivo* activity of certain chemokines. *Proc Natl Acad Sci U S A* 100: 1885–1890.
23. Sadir R, Imberty A, Baleux F, Lortat-Jacob H (2004) Heparan sulfate/heparin oligosaccharides protect stromal cell-derived factor-1 (SDF-1)/CXCL12 against proteolysis induced by CD26/dipeptidyl peptidase IV. *J Biol Chem* 279: 43854–43860.
24. Sweeney EA, Lortat-Jacob H, Priestley GV, Nakamoto B, Papayannopoulou T (2002) Sulfated polysaccharides increase plasma levels of SDF-1 in monkeys and mice: involvement in mobilization of stem/progenitor cells. *Blood* 99: 44–51.
25. Valenzuela-Fernandez A, Palanche T, Amara A, Magerus A, Altmeyer R, et al. (2001) Optimal inhibition of $\times 4$ HIV isolates by the CXC chemokine stromal cell-derived factor 1 alpha requires interaction with cell surface heparan sulfate proteoglycans. *J Biol Chem* 276: 26550–26558.
26. Gleichmann M, Gillen C, Czardybon M, Bosse F, Greiner-Petter R, et al. (2000) Cloning and characterization of SDF-1gamma, a novel SDF-1 chemokine transcript with developmentally regulated expression in the nervous system. *Eur J Neurosci* 12: 1857–1866.
27. Yu L, Cecil J, Peng SB, Schrementi J, Kovacevic S, et al. (2006) Identification and expression of novel isoforms of human stromal cell-derived factor 1. *Gene* 374: 174–179.
28. Laguri C, Sadir R, Rueda P, Baleux F, Gans P, et al. (2007) The Novel CXCL12gamma Isoform Encodes an Unstructured Cationic Domain Which Regulates Bioactivity and Interaction with Both Glycosaminoglycans and CXCR4. *PLoS ONE* 2: e1110.
29. Allen CD, Ansel KM, Low C, Lesley R, Tamamura H, et al. (2004) Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5. *Nat Immunol* 5: 943–952.
30. Coulomb-L'Hermin A, Amara A, Schiff C, Durand-Gasselini I, Foussat A, et al. (1999) Stromal cell-derived factor 1 (SDF-1) and antenatal human B cell lymphopoiesis: expression of SDF-1 by mesothelial cells and biliary ductal plate epithelial cells. *Proc Natl Acad Sci U S A* 96: 8585–8590.
31. Amara A, Lorthioir O, Valenzuela A, Magerus A, Thelen M, et al. (1999) Stromal cell-derived factor-1alpha associates with heparan sulfates through the first beta-strand of the chemokine. *J Biol Chem* 274: 23916–23925.
32. Sandhoff R, Grieshaber H, Djafarzadeh R, Sijmonsma TP, Proudfoot AE, et al. (2005) Chemokines bind to sulfatides as revealed by surface plasmon resonance. *Biochim Biophys Acta* 1687: 52–63.
33. Altenburg JD, Broxmeyer HE, Jin Q, Cooper S, Basu S, et al. (2007) A naturally occurring splice variant of CXCL12/stromal cell-derived factor 1 is a potent human immunodeficiency virus type 1 inhibitor with weak chemotaxis and cell survival activities. *J Virol* 81: 8140–8148.
34. Jones KS, Petrow-Sadowski C, Bertolette DC, Huang Y, Ruscetti FW (2005) Heparan sulfate proteoglycans mediate attachment and entry of human T-cell leukemia virus type 1 virions into CD4+ T cells. *J Virol* 79: 12692–12702.
35. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, et al. (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. *Cell* 121: 335–348.
36. Passaniti A, Taylor RM, Pili R, Guo Y, Long PV, et al. (1992) A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. *Lab Invest* 67: 519–528.
37. Segret A, Rucker-Martin C, Pavoine C, Flavigny J, Deroubaix E, et al. (2007) Structural localization and expression of CXCL12 and CXCR4 in rat heart and isolated cardiac myocytes. *J Histochem Cytochem* 55: 141–150.
38. Stumm RK, Rummel J, Junker V, Culsme C, Pfeiffer M, et al. (2002) A dual role for the SDF-1/CXCR4 chemokine receptor system in adult brain: isoform-selective regulation of SDF-1 expression modulates CXCR4-dependent neuronal plasticity and cerebral leukocyte recruitment after focal ischemia. *J Neurosci* 22: 5865–5878.
39. Nickel W (2007) Unconventional secretion: an extracellular trap for export of fibroblast growth factor 2. *J Cell Sci* 120: 2295–2299.
40. Brelot A, Heveker N, Adema K, Hosie MJ, Willett B, et al. (1999) Effect of mutations in the second extracellular loop of CXCR4 on its utilization by human and feline immunodeficiency viruses. *J Virol* 73: 2576–2586.
41. Soriano SF, Hernandez-Falcon P, Rodriguez-Frade JM, De Ana AM, Garzon R, et al. (2002) Functional inactivation of CXC chemokine receptor 4-mediated responses through SOCS3 up-regulation. *J Exp Med* 196: 311–321.
42. Ferrara N, Alitalo K (1999) Clinical applications of angiogenic growth factors and their inhibitors. *Nat Med* 5: 1359–1364.
43. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, et al. (1991) The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. *J Biol Chem* 266: 11947–11954.
44. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z (1999) Vascular endothelial growth factor (VEGF) and its receptors. *Faseb J* 13: 9–22.
45. Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N (1992) Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. *J Biol Chem* 267: 26031–26037.
46. Ruhrberg C, Gerhardt H, Golding M, Watson R, Ioannidou S, et al. (2002) Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. *Genes Dev* 16: 2684–2698.
47. Ferrara N (1999) Vascular endothelial growth factor: molecular and biological aspects. *Curr Top Microbiol Immunol* 237: 1–30.
48. Sadir R, Baleux F, Grosdidier A, Imberty A, Lortat-Jacob H (2001) Characterization of the stromal cell-derived factor-1alpha-heparin complex. *J Biol Chem* 276: 8288–8296.
49. Staropoli I, Chanel C, Girard M, Altmeyer R (2000) Processing, stability, and receptor binding properties of oligomeric envelope glycoprotein from a primary HIV-1 isolate. *J Biol Chem* 275: 35137–35145.
50. Lagane B, Ballet S, Planchenault T, Balabanian K, Le Poul E, et al. (2005) Mutation of the DRY motif reveals different structural requirements for the CC chemokine receptor 5-mediated signaling and receptor endocytosis. *Mol Pharmacol* 67: 1966–1976.
51. Balabanian K, Harriague J, Decrion C, Lagane B, Shorte S, et al. (2004) CXCR4-tropic HIV-1 envelope glycoprotein functions as a viral chemokine in unstimulated primary CD4+ T lymphocytes. *J Immunol* 173: 7150–7160.
52. Balabanian K, Lagane B, Pablos JL, Laurent L, Planchenault T, et al. (2005) WHIM syndromes with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12. *Blood* 105: 2449–2457.
53. Pablos JL, Santiago B, Galindo M, Torres C, Brehmer MT, et al. (2003) Synovial cell-derived CXCL12 is displayed on endothelium and induces angiogenesis in rheumatoid arthritis. *J Immunol* 170: 2147–2152.
54. Zimrin AB, Villeponteau B, Maciag T (1995) Models of *in vitro* angiogenesis: endothelial cell differentiation on fibrin but not matrigel is transcriptionally dependent. *Biochem Biophys Res Commun* 213: 630–638.